Cesano Alessandra sold $567K of PBYI
Cesano Alessandra sold 62,150 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $9.12 ($0.57M total) on 2026-09-14 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and pre‑arranged, suggesting limited immediate market impact but worth noting for ownership tracking.
Market read
Provides a fresh insider transaction for a small‑cap biotech, useful for ownership monitoring but low trading urgency.
What to watch
Potential upcoming clinical trial results or FDA decisions that may have prompted the timing of the plan.
Background
SEC Form 4 filings disclose insider transactions; investors monitor them for signals of insider sentiment.
Ticker impact
Director Cesano Alessandra sold 62,150 shares for $567K via a 10b5-1 plan on Sep 14, 2026.
Minor downward pressure; price may dip a few cents if market reacts.
The sale size is modest relative to market cap and follows a 10b5‑1 plan, suggesting no urgent information.
Market effects
Limited; biotech sector unlikely to be affected by a single insider sale.
None; the filing is U.S.‑focused.
Low; only relevant to Puma Biotechnology investors.
Counterpoint
The sale could signal insider confidence if the 10b5‑1 plan was set earlier and not driven by new negative information.
Key entities
- CompanyPuma Biotechnology, Inc.
Biotech firm listed on NASDAQ under ticker PBYI.
- InsiderCesano Alessandra
Director of Puma Biotechnology who filed the Form 4.
